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Discovery and Characterization of Circular and Chimeric RNAs in Complex Diseases 
by Xiaoxin Liu 
Doctor of Philosophy in Computer Science 
Washington University in St. Louis, 2021 
Professor Weixiong Zhang, Chair 
Non-co-linear RNAs, including circular and chimeric RNAs, have been investigated in a broad 
range of cellular processes and various diseases. The current biogenesis models of circular and 
chimeric RNAs depend on RNA splicing mechanisms. We hypothesized that some of the non-co-
linear RNAs are products of an alternative mechanism other than RNA splicing. To test this 
hypothesis, we developed a method, which is independent of genome annotations and splicing 
signals, to identify Circular and Chimeric RNAs of All Types (C2AT or CAT for simplicity) by 
analyzing the RNA species profiled by whole genome RNA sequencing. Statistical analysis and 
experimental validation revealed that both circular RNAs (circRNAs) and chimeric RNAs may 
arise from the interior regions of exons and introns across the human genome, supporting a 
potential novel mechanism of biogenesis of circular and chimeric RNAs. Moreover, analysis of 
differential expressions of circRNAs and chimeric RNAs and their host genes suggested that these 
non-co-linear RNAs may play an important role in complex diseases, such as cancer and psoriasis. 
All the results from this systematic study of non-co-linear RNAs significantly expanded our 
understanding of the origin, diversity, and complexity of circRNAs and chimeric RNAs as well as 
their potential functions in complex diseases.
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Chapter 1. Introduction 
The advent and development of high-throughput RNA sequencing technology have revolutionized 
the research on linear RNAs and non-co-linear RNAs, which consist of two or more RNA segments 
that are topologically inconsistent with their DNA counterparts in the reference genome. While 
linear RNAs, e.g., messenger RNAs (mRNAs) and long noncoding RNAs, have been studied for 
decades, non-co-linear RNAs, mainly circular and chimeric RNAs, are a relatively less scrutinized 
class, which are more complex in their structures and biogenesis. Chimeric RNAs are composed 
of sequence segments from two or more primary RNA transcripts, whereas circular RNAs 
(circRNAs) are formed in a closed circle structure by linking the 5’ and 3’ ends of RNA molecules.  
1.1 Circular RNA 
Circular RNA (circRNA) is a class of non-coding RNA, which appears in a single-stranded, 
covalently closed circular form [1, 2]. As first reported in RNA viruses [3] and eukaryotes [2] 
decades ago, circRNAs were thought to be a result of erroneous splicing of transcripts for a long 
time. With the development of RNA sequencing technology (RNA-seq), many genome-wide 
sequencing-based RNA profilings have revealed that circRNAs exist broadly in animals [4-7], 
plants [8, 9], and nearly all eukaryotic species [10].  
Functional analysis has suggested many molecular functions of circRNAs, including promoting 
transcription [11], competing with canonical splicing [12], and influencing the expression of 
mRNA [13] and protein [12]; some circRNAs may even be translated into polypeptide [14, 15]. 
circRNAs exhibit expression patterns that are specific to cell types and tissues [16-21] as well as 
development stages [17, 22]. Some circRNAs have been shown to have aberrant expressions in 
complex diseases, such as cancer [23-25], osteoarthritis [26], cardiovascular diseases [27, 28], and 
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Alzheimer’s disease (AD) [29], and may consequently play a role in disease onset and progression. 
The most well-studied circRNA CDR1as [7], also known as ciRS-7 [6], originates from the 
noncoding transcript antisense to a gene encoding Cerebellar Degeneration-Related protein 1 
(CDR1) on human chromosome X. It carries more than 70 binding sites of microRNA (miRNA) 
miR-7, and thus acts as a sponge of miR-7 [6, 7]. miR-7 is a “master” regulator of many signaling 
pathways via mediating other regulating factors, including epidermal growth factor receptor 
(EGFR), insulin receptor substrate-1 (IRS-1), IRS-2, p21-activated kinase-1 (Pak1), and Raf1 [23, 
25, 30], to name a few. CDR1as is enriched in human and mouse brains and neurons [6, 7, 17] and 
thus expected to be involved in neurodegenerative diseases through the CDR1as-miR-7-targets 
gene regulatory cascade.  
Most of the reported circRNAs contain exclusively exons or exons and introns [31-33], and these 
circRNAs join at intron-exon junctions, suggesting that they are products of the splicing apparatus 
[34-39] (Figure 1A). Indeed, the formation of some of these circRNAs has been shown to require 
canonical splicing signals [40] and to involve exon skipping [41, 42]. Furthermore, it has been 
revealed that trans-acting RNA-binding proteins and reverse complementary repeat sequences, 
e.g., Alu elements in human, in adjacent introns help bring the 3’-end of an exon and the 5’-end 
of the exon or an upstream exon to close vicinity in the cell and subsequently join the two ends of 
the linear transcript to help form a circRNA [43-47]. 
Intergenic regions have been indicated to host circRNAs [35]. Yet most recent studies have 
focused on circRNAs originated from intron-exon junctions. Particularly, the existing circRNA 
identification methods zoom onto genomic loci of intron-exon boundaries and capitalize on the 
annotated splicing signals of splicing donor and receptor sites on the genome [48-50]. However, it 
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remains unresolved if intron-exon junctions are the only genomic origin for circRNA production 
and if splicing is the only mechanism underlying circRNA biogenesis.  
 
Figure 1. Mechanisms of circular RNA and chimeric RNA formation. (A) Direct backsplicing and lariat-
driven backsplicing can lead to the formation of circRNAs, and splicing signals, such as AG-GT, are always 
involved in the process of circularization. (B) Chimeric RNAs can be formed by both structural 
rearrangements and non-structural rearrangements. Structural rearrangements of chromosomes include 
transforms such as insertion, deletion, translocations and inversions. Non-structural rearrangements may 
happen during the process of transcription, i.e. transcription read-through of neighboring genes, or after the 
process of transcription, i.e. splicing of mRNA molecules.  
 
1.2 Chimeric RNA 
Chimeric RNA, also known as fusion transcript, is composed of sequence segments from two or 
more different transcripts (Figure 1B). The first described chimeric RNA was BCR/ABL1 in cancer 
cells in the early 1980s, which was generated by chromosomal rearrangement between 
chromosome 9 and chromosome 22 [51]. Since then, chimeric RNAs have been discovered broadly 
in almost all types of human neoplasia and even in lower eukaryotes such as nematodes and 
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trypanosomes [52, 53]. Recently, advances in next-generation sequencing have helped identify 
more putative chimeric RNAs. For instance, the ChimerDB database has maintained more than 
60,000 fusion transcripts in various types of cancer as well as normal tissues of humans [54].  
The most well-known function of chimeric RNAs is to encode novel chimeric proteins [55]. Many 
chimeric RNAs and their corresponding protein products are associated with oncogenic properties 
and often act as driver genes in various cancers. For example, chimeric RNA SLC45A3-ELK4 and 
TMPRSS2-ERG are promising biomarkers for prostate cancer [56];  BCR-ABL, FUS-ERG, MLL-
AF6, and MOZ-CBP are expressed in acute myeloid leukemia (AML) [57, 58]; EML4–ALK may 
function as a therapeutic target and a diagnostic molecular marker in non-small-cell lung cancer 
(NSCLC) [59]. In addition to cancers, some chimeric RNAs are also found to be related to some 
other diseases. Chimeric RNA CFHR5–CFHR2 was identified to cause familial C3 
glomerulonephritis [60]. TEL-Syk was reported to be expressed in patients with myelodysplastic 
syndrome and involved in the pathogenesis of hematopoietic malignancies [61]. A comprehensive 
genetic study of two siblings affected by Autism spectrum disorder (ASD) and their unaffected 
parents suggested that chimeric transcript ELMOD3-SH2D6 may play a role in ASD, together with 
other well-established variants such as copy number variants [62]. However, the research on 
chimeric RNAs in complex diseases remains to be relatively rare compared to that on various types 
of cancers.  
Most chimeric RNAs can be translated into proteins. However, fusion proteins are often expressed 
with low abundance and tissue specific [63]. Despite that a large number of chimeric transcripts 
have been reported, only a few fusion proteins have been confirmed so far. Fusion transcripts and 
proteins are not only expressed in cancers but also present in normal tissues with unclear functions 
[64].  
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Two biogenesis models have been established for chimeric RNA formation, i.e., structural 
rearrangement in DNA and transcriptional rearrangement in RNA [63] (Figure 1B). In the model 
of structural rearrangement, the structures of chromosomes may change in different ways, such as 
translocations, inversions, deletions, and insertions, leading to the formation of fusion genes. These 
fusion genes may then be transcribed into chimeric RNAs and further translated into fusion 
proteins. In transcriptional rearrangement, trans-splicing or cis-splicing of RNAs may occur 
between different mRNA molecules and transcription read-through may happen between adjacent 
genes, resulting in fusion transcripts that may be translated into fusion proteins. According to these 
two mechanisms, chimeric RNAs are composed of exons from different genes or mRNAs, and the 
existing chimeric RNA identification methods focus on genomic loci of intron-exon boundaries 
and depend on the annotated exons, introns, and intergenic regions. However, it remains an open 
question if intron-exon junctions are the only genomic origin for chimeric RNA generation, and if 
the above two mechanisms are the only biogenesis mechanisms for chimeric RNA production.  
1.3 Hypothesis and research objectives 
The existing studies of circular and chimeric RNAs focus exclusively on the candidate transcripts 
originating from canonical intron-exon junctions. Inspired by the result that intergenic regions can 
host circRNAs [35], we challenge this common wisdom and hypothesize that circular and chimeric 
RNAs can arise in other genomic loci across the genome, particularly from the regions inside of 
introns and exons. 
To validate this hypothesis, we develop an integrative computational algorithm without using any 
information of splicing signals and genome annotation to search for fusion junctions of circRNAs 
and chimeric RNAs from any genomic locus which are captured in RNA-seq data. With this 
algorithm, we carry out systematic studies using several large sets of RNA-seq data collected from 
 6 
plants and humans. Besides canonical circRNAs and chimeric RNAs originating from intron and 
exon junctions, we are particularly interested in noncanonical circular and chimeric RNAs that are 
produced from other regions of the genome, such as interior regions of exons and introns. Some 
of these novel, noncanonical RNAs are further experimentally validated using Polymerase Chain 
Reactions (PCR) followed by the Sanger sequencing.  
Furthermore, we further hypothesize that the noncanonical circular and chimeric RNAs are 
functional. This is inspired by the results that canonical circular RNAs can regulate gene 
transcription by acting as miRNA sponges [65] or competing with canonical splicing [12] and 
chimeric RNAs may also function as competing endogenous RNAs by retaining miRNA binding 
sites [66]. Therefore, circular and chimeric RNAs may potentially act as regulators in the cell.  
To study the second hypothesis, we adopt systems biology approaches to explore the 
characteristics, functions, and biogenesis of circular and chimeric RNAs in complex diseases. 
Statistical methods are applied to search for sequence and structure patterns from the identified 
circular and chimeric RNAs, especially from the sequences near the fusion points. We perform 
differential expression analysis and pathway enrichment on circular and chimeric RNAs in 
complex diseases such as prostate cancer and psoriasis. Moreover, significant differentially 
expressed (DE) circRNAs and chimeric RNAs, particularly the noncanonical ones, are scanned for 
potential functions, such as binding miRNAs and competing with mRNAs. Some of these DE 










Chapter 2. Discovery of all types of circular and chimeric RNAs 
Here, we develop a new algorithm to identify circular and chimeric RNAs that arise from inside 
of exons, introns, and intergenic transcripts without genome annotation and apply the method to 
analyze these non-co-linear RNAs in humans (Homo sapiens) and Arabidopsis (Arabidopsis 
thaliana). To distinguish them from the reported circular and chimeric RNAs over intron-exon 
junctions, we name such novel type as interior circRNAs (i-circRNAs for short) and interior 
chimeric RNAs. 
2.1 Identification method 
Many methods have been developed for circRNA identification, but most of them utilize splicing 
signals or gene annotations to facilitate the discovery of back fusion points (BF points), such as 
find_circ [7], CIRCexplorer2 [67], ACFS [68] and KNIFE [50]. A new circRNA identification 
method was developed to search for all possible back fusion points (BF points) that are captured 
in RNA-seq data without using any information of splicing signals and genome annotation.  
2.1.1 Identification of circRNAs of all types 
A new method was developed to comprehensively search for circular RNAs of all types (i.e., the 
CAT method) using RNA-seq data without information of splicing signals. CAT first maps 
sequencing reads to the reference genome with Bowtie2 [69]. The mappable reads are discarded 
since they are from linear RNAs. CAT takes a left and a right x-mer on the 5’-end and 3’-end of 
an unmapped read, called the left and right anchors, respectively (Figure 2A). It attempts to split-
map the read to the genome – the left anchor maps to a locus that is downstream from the locus to 
which the right anchor maps. If successful, it then searches for the split point within the sequence 
between the two anchors such that when the read is split at the split point, the two segments of the 
read can be aligned to the genomic loci that the anchors determine (Figure 2A). In the current CAT 
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implementation for sequencing read length of 100bp, x was initially set to 20, and no more than 
two mismatches were allowed in mapping.  
Figure 2. Two key elements for identification of circRNAs and classification of circRNAs. (A) The first 
key element is split mapping of RNA-seq reads to candidate circRNAs, particular i-circRNAs, which may 
originate from an interior region of an exon, an intron or a pair of adjacent exon and intron. (B) The second 
key element is to avoid ambiguity in distinguishing a canonical circRNA or i-circRNA spanning over more 
than one exon using RNA-seq data alone, particularly data from an RNA library preparation protocol where 
circRNAs are not enriched. Shown here are two exons from which two possible linear RNAs, one from 
splicing and the other from back splicing, and a circular RNA may be produced independently. It is difficult 
to distinguish the circRNA from the linear RNAs when they appear together using RNA-seq data alone. To 
this end, the analysis here focuses on candidate circRNAs from one exon, one intron, or an adjacent exon 
and intron pair. (C) Classification of i-circRNAs.  An i-circRNA may have four possible positions relative 
to the intron-exon boundaries of its originating transcript. A more elaborate scenario involves an i-circRNA 
from locus with more than one gene annotation. Two types of gene annotation may appear, one where an 
exon encompasses another exon and the other where two exons are partially overlapped. Regardless of 
which of the two types occurs, it is sufficient to consider only the overlapping region. Based on the relative 
position of the i-circRNA and the overlapping region, the i-circRNA can be classified into a complete i-
circRNA (or i-circRNA) or partial i-circRNA where one of the back fusion points of the i-circRNA is 
aligned to one of the boundaries of the overlapping region.  
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CAT retains those BF points that are supported by at least k (e.g., k>2 in most of our analyses) 
split-mapped reads in an RNA-seq library. Furthermore, only unambiguous candidate BF points 
are considered by setting a threshold for quality score. The quality score is defined as the score 
difference between the best mapping and the second-best mapping of the anchors, so the larger the 
better. In our analysis, we usually set the threshold for the quality score as 40, which is the largest 
possible value for a quality score.  
Specifically, while there certainly exist circRNAs spanning more than one exon, it is difficult to 
infer such circRNAs with certainty based on RNA-seq data alone, particularly on RNA libraries 
not enriched for circRNAs (Figure 2B). Therefore, only candidate circRNAs from single introns, 
single exons, pair of adjacent exons and introns, and intergenic non-coding transcripts are 
considered, including canonical circRNAs over intron-exon junctions and interior circRNAs (i-
circRNAs) arising from the interior regions of exons and introns (Figure 2C), if RNA-seq libraries 
are not RNase R treated. 
An i-circRNA may have a few possible positions relative to its originating RNA transcript (Figure 
2C). Consider a simple case of a transcript consisting of a single exon. In addition to possibly 
giving rise to a circRNA by circularization on its 5’-end and 3’-end, it may host an i-circRNA 
completely interior to the transcript, which is referred to as complete i-circRNA or simply i-
circRNA. Besides, it may generate an i-circRNA starting from its 5’-end and ending in the middle 
of the transcript or an i-circRNA starting in the middle and ending at its 3’-end, any of which is 
referred to as a partial i-circRNA (Figure 2C). It is more involved when the originating transcript 
is from a genomic locus that is annotated to have more than one gene structure. Regardless, it is 
sufficient to focus on the common region of two or multiple overlapping exons and/or introns 
(Figure 2C), and reason about the position of the circRNA with respect to the common region 
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following the same rules for classifying i-circRNAs into complete i-circRNAs and partial i-
circRNAs (Figure 2C). i-circRNAs from intergenic regions are analyzed and classified in reference 
to the currently annotated intergenic noncoding transcripts, if available, and transcripts assembled 
using the same RNA-seq data that are employed to detect circRNAs. 
2.1.2 Performance of CAT for circRNA identification 
CAT supports RNA-seq data from different RNA library preparation protocols, including RNA 
library preparation with ribosome depletion and RNase R treatment as well as stranded or 
unstranded sequencing. We compared CAT with four most popular existing methods for circRNA 
detection, i.e., CIRI2 [70], CIRCexplorer2 [67], DCC [71], and find_circ [7] (Table 1). These 
methods share a common feature of relying on the genome annotation and/or the splicing signals 
for calling circRNAs, and all these methods, except DCC, ignore the strand specificity even if such 
information is available in data from strand-specific sequencing. These features led to two serious 
consequences, which were adequately dealt with in CAT. First, they completely ignore the 
circRNAs arising from the interior regions of introns and exons and intergenic transcripts which 
are typically poorly annotated and are often not associated with splicing signals. Second, ignoring 
strand specificity can erroneously designate a circRNA to the wrong strand.  
Table 1. circRNA identification algorithms 
Tool Version Language Mapper Signal? Annotation? URL 
find_circ N/A Python Bowtie2 Yes No http://www.circbase.org/ 
CIRI2 2.0.6 Perl Bwa Yes No https://sourceforge.net/projects/ciri/files/CIRI2/ 
CIRCexplorer2 2.3.8 Python Tophat No Yes https://circexplorer2.readthedocs.io/en/latest/ 
DCC 0.4.7 Python STAR No No https://github.com/dieterich-lab/DCC 
CAT N/A Python Bowtie2 No No https://github.com/xiaoxin8712/CAT 
CAT had an estimated error rate that was comparable with that of the other four methods. In a 
comparative analysis for estimating the error rates of these five methods, we used two datasets, a 
single-end dataset of HeLa cell (GSE130905) and a paired-end dataset of prostate cancer cell lines 
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(GSE113120). Each dataset contains two sets of RNA-seq data, one set from a ribosome-depletion 
protocol and the other from a protocol of ribosome-depletion followed by RNase R treatment 
which removes linear RNAs (Figures 3A and 3B). In this comparison, all these methods used the 
most stringent read-mapping quality and a circRNA was claimed to be identified by a method if it 
detected at least k (k=3 for HeLa and k=12 for prostate cancer) RNA-seq reads across the back-
splicing or back-fusion point of the circRNA with a threshold of a quality score as 40. Taken the 
RNase R treatment as the gold standard for circRNA detection, we estimated the error rate of a 
method on the ribosome-depletion data by comparing the results from the ribosome-depletion data 
and data of ribosome depletion followed by RNase R treatment, a scheme proposed in [72]. Among 
the methods compared in HeLa, DCC had the highest estimated error rate of 13.93%, find_circ 
had the smallest estimated error rate of 8.35%, and the estimated error rate of CAT was ~3% lower 
than that of DCC and ~2% higher than that of find_circ. In prostate cancer, CIRCexplorer2 had 
the highest estimated error rate of 8.70%, find_circ had the smallest estimated error rate of 2.49%, 
while the estimated error rate of CAT was ~4% lower than that of CIRCexplorer2 and ~1.5% 
higher than that of find_circ. Moreover, the comparative analysis revealed that to reduce the 
possible erroneous calling of all types of circRNA, it was important to adopt stringent criteria for 
detecting circRNAs, including the read mapping quality and the minimal number of supporting 
reads mapped to the back-fusion point of a circRNA (Figures 3C-E).  
The ability to detect i-circRNAs enables CAT to report more novel circRNAs and improves the 
error rate as well. In HeLa cell, CAT had an estimated error rate of 9.06% for boundary circRNAs, 
and the estimated error rate for i-circRNAs was 17.83%, higher than that for boundary circRNAs 
(Figure 3F). Most of the i-circRNAs are bonafide circRNAs, even though many i-circRNAs are 
 12 
not as stable as boundary circRNAs and the expressions of these i-circRNAs may be transient and 
abundant in nascent RNAs, which we will discuss in detail in Section 2.3.  
Figure 3. Specificity and sensitivity of circRNA identification methods. Stacked barplot of all predicted 
circRNAs in (A) HeLa (RNase R vs. Control) and (B) prostate cancer cell lines (RNase R vs. Control)  
stratified by RNase R resistant (>= 5 fold enrichment, green), unaffected (1-5 fold enrichment, gray) and 
RNase R sensitive (depleted in RNase R treated samples, red), as denoted. Percentage reflects the fraction 
of RNAse R sensitive circRNAs defined as false positives. The minimal number of supporting reads was 
set to be 3 in (A) HeLa and 12 in (B) prostate for all algorithms. The influence of different parameters on 
the specificity and sensitivity is shown for (C) CAT, (D) DCC, and (E) CIRI2 in HeLa. For example, f2_35 
means that the minimal number of supporting reads is set to be 2 and the quality score is set to be 35, while 
f3_40 means that the minimal number of supporting reads is set to be 3 and the quality score was set to be 
40. (F) Stacked barplot of boundary and interior circRNAs predicted by CAT in HeLa when the minimal 
number of supporting reads is set to be 3. 
2.1.3 Identification of chimeric RNAs of all types 
The method CAT for finding circRNAs can be revised to detect chimeric RNAs. If the unmappable 
read can be split mapped to more than one gene, which are on the same strand, on different strands, 
or even on different chromosomes, then the fusion point is considered as an important piece of 
evidence for chimeric RNA (Figure 4A). The filtering criteria for circRNAs, i.e., the number of 
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supporting reads k and mapping quality scores, are also applied to increase identification accuracy. 
As a chimeric RNA is originated from two genes, gene annotations are used in our method to filter 
out candidates from the same genes. However, we are not using splicing signals or prior knowledge 
of genome annotation to find the fusion junctions as other methods do, such as FusionFinder [73], 
FusionHunter [74], and JAFFA [75]. The information of gene structures is only used to determine 
the types of chimeric RNAs identified, either canonical chimeric RNAs or interior chimeric RNAs. 
 
Figure 4. Identification and classification of chimeric RNAs. (A) Split mapping of RNA-seq reads to 
candidate chimeric RNAs, which may originate from an interior region of an exon or an intron of two or 
more genes. (B) Sensitivity and number of false positives for eight chimeric RNA identification methods. 
The number of true positives was shown together with the total number of artificially created true positives 
in parenthesis. (C) Classification of chimeric RNAs.  A chimeric RNA may have three possible positions 
relative to the intron-exon boundaries of its originating transcript. Based on the relative position of the 
chimeric RNA and the known boundaries, the chimeric RNAs can be classified into a canonical chimeric 
RNA, complete interior chimeric RNA or partial interior chimeric RNA where one of the fusion points of 
the chimeric RNA is aligned to one of the intron-exon boundaries. (D) Distribution of chimeric RNAs in 
tumor and normal tissues of prostate cancer, and psoriatic-involved (PP) lesions and normal (NN) controls 
of skin tissues.  Cutoff for the number of supporting reads in at least one sample is set to be 5.  
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To evaluate the performance of CAT on chimeric RNA detection, we compared CAT with seven 
popular existing tools (Table 2) for fusion transcript detection. We tested and compared these 
methods using an artificially created fusion transcript dataset [76], which contained 50 true fusion 
transcripts. CAT had the lowest number of false positives and the second-highest sensitivity among 
all eight methods compared (Figure 4B).  
Table 2. Chimeric RNA identification algorithms 
Tool Name Group Language Exon? URL 
FusionFinder Paired/Single-end Perl Yes https://sourceforge.net/projects/fusionfinder/ 
TopHat-Fusion Paired/Single-end Tophat No http://ccb.jhu.edu/software/tophat/fusion_index.shtml 
MapSplice Paired/Single-end Python Yes http://www.netlab.uky.edu/p/bioinfo/MapSplice 
defuse Paired-end C++, Perl, R No https://shahlab.ca/projects/defuse/ 
FusionHunter Paired-end Perl Yes https://github.com/leofountain/FusionHunter 
SOAPfuse Paired-end Perl No https://github.com/Nobel-Justin/SOAPfuse 
JAFFA Paired/Single-end Bash, R Yes https://github.com/Oshlack/JAFFA/wiki 
CAT Paired/Single-end Python No https://github.com/xiaoxin8712/CAT 
 
To reiterate, CAT uses no information of splicing signals or exon/intron boundaries for chimeric 
RNA detection but instead uses genome annotation to classify chimeric RNAs into the categories 
of conventional chimeric RNAs with two fusion points at exon or intron boundaries, complete 
interior chimeric RNAs with both fusion points not at exon or intron boundaries, and partial 
interior chimeric RNAs with one fusion point from exon or intron boundaries (Figure 4C).  
Table 3. Descriptions of four datasets of stranded RNA-seq used for chimeric RNA identification 
Dataset Organism Tissue Library No. of Samples Accession 
Tumor Homo sapiens Prostate Ribominus 30 GSE133626 
Normal Homo sapiens Prostate Ribominus 30 GSE133626 
PP Homo sapiens Skin Ribominus 28 GSE121212 
NN Homo sapiens Skin Ribominus 38 GSE121212 
 
Besides, we applied CAT to four collections of stranded RNA-seq data from tumor and normal 
tissues of human prostate cancer, psoriatic-involved (PP) lesions, and normal (NN) controls of 
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human skin (Table 3).  We identified a large number of chimeric RNAs, many of which were 
interior chimeric RNAs residing inside of introns, exons, and intergenic regions. In the tumor, 
normal, PP and NN dataset, 1880 (72.8% of the total), 1839 (73.3%), 985 (75.8%) and 1135 
(72.0%) of the chimeric RNAs that we detected were interior chimeric RNAs when the number of 
supporting reads in at least one sample was not less than 5, among which 1772, 1784, 953 and 
1103 were complete interior chimeric RNAs, respectively (Figure 4D). Interestingly, there exist 
more interior chimeric RNAs than canonical chimeric RNAs, and complete interior chimeric RNAs 
constitute a large part of all chimeric RNAs of the two tissues that we profiled (Figure 4D). Not 
surprisingly, a portion of interior chimeric RNAs does not carry splicing signals. In particular, 
among the complete interior chimeric RNAs, 271 (15.3%), 200 (11.2%), 219 (23.0%) and 232 
(21.0%) are not adjacent to splicing signals in the tumor, normal, PP and NN dataset, respectively 
(Figure 4D). 
2.2 Interior circRNAs are ubiquitous in eukaryotes 
We applied CAT to five collections of stranded RNA-seq data from human (HeLa cells, prostate 
cancer cell lines, normal brain, and normal liver tissues) and Arabidopsis (inflorescences) (Table 
4). We identified a large number of circRNAs, many of which were i-circRNAs residing inside of 
introns, exons, and intergenic regions.  
In HeLa cells, prostate cancer cell lines, Arabidopsis inflorescences, human normal brain and liver 
tissues, 641 (92.2% of the total), 664 (55.1%), 304 (95.9%), 87 (56.5%) and 32(69.6%) of the 
circRNAs that we detected were i-circRNAs, among which 515, 313, 251, 72 and 27 were 
complete i-circRNAs, respectively (Figure 5A). Interestingly, there exist more i-circRNAs than 
canonical circRNAs, and complete i-circRNAs constitute a large part of all circRNAs of the two 
organisms that we profiled (Figure 5A). Remarkably, most i-circRNAs do not carry splicing 
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signals, i.e., their back fusion points are not adjacent to splicing signals of the major or minor 
splicing donor and receptor sites (Figure 5A).  
Table 4. Descriptions of five collections of stranded RNA-seq data 
Dataset Library Samples Accession 
HeLa cells (in-house) RNase R treated 4 GSE119938  
Prostate cancer cell lines RNase R treated 2 samples for each cell line: 22Rv1, 
V16A, PC-3 and 42D, 4 samples for 
LNCaP. 
GSE113120 
Normal brain tissues Ribominus 2 GSE77661 
Normal liver tissues Ribominus 2 GSE77661 
Arabidopsis RNase R treated 4 GSE117416 
 
The circRNAs detected in HeLa cells were genuine circRNAs since a stranded RNA extraction 
method with a ribo-zero protocol (to preserve noncoding RNAs) plus RNase R treatment (to 
remove linear transcripts) was adopted in RNA-seq library preparation. To further confirm the i-
circRNA candidates that we identified to be bona fide i-circRNAs, 14 complete i-circRNAs and 2 
canonical circRNAs from HeLa cells were chosen for experimental validation. Divergent PCR 
primers were designed and applied separately to the RNA and DNA of the circRNAs to be 
validated. The circRNAs that were detected in RNA but not in DNA were further subjected to 
Sanger sequencing for confirmation (Figures 5B-C and Figures 8B-D). Note that Sanger 
sequencing successfully recovered the full-length structure of an intronic i-circRNAs 
hsa_circ_0092378. In our experiments, we also included hsa_circ_0005035 and 
has_circ_0092379, a canonical circRNA from the second exon of gene IGF1R on human 
chromosome 15 and a canonical circRNA from the first exon of gene RMRP on human 
chromosome 9, respectively, as positive controls (Figures 5B and 8B). In total, 5 (35.7% of 14) i-
circRNAs and 2 (100% of 2) canonical circRNAs in HeLa cells were experimentally validated. 
One possible reason for not being able to detect all 14 i-circRNAs using PCR was the significantly 
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lower expression abundance of i-circRNAs than canonical circRNAs in HeLa cells – the former 
was on average nearly one order of magnitude lower than the latter (Figure 5D). Combined, the 
results showed that i-circRNAs exist in animal and plant species, which are in concordance with 
the previous results that circRNAs appear in nearly all branches of life [10]. 
 
Figure 5. Distribution and validation of circRNAs. (A) Distribution of circRNAs in HeLa cells, prostate 
cancer cell lines, Arabidopsis inflorescences, human normal brain and liver tissues when number of 
supporting reads in at least one sample k = 5 and threshold for quality score is set as 35. (B) Validation of 
a canonical circRNA (has_circ_0005035) and two i-circRNAs in HeLa cells by PCR. The divergent and 
convergent arrows above the gel image represent, respectively, the divergent and convergent PCR primers 
used, and the white arrows in the gel image point to circRNAs. Here, hsa_circ_0005035, a canonical 
(exonic boundary) circRNA, was used as a positive control, hsa_circ_0092378 is an intronic i-circRNAs 
and hsa_circ_0092377 is an exonic i-circRNA. Gene GRAPDH was used as an internal control. (C) The 
genomic origin of intronic i-circRNA hsa_circ_0092378, its circular structure and back-fusion points 
(BFPs), and the results from RNA-seq and the Sanger sequencing. (D) Average expression levels 
(quantified by RNA-seq reads) of canonical circRNAs and i-circRNAs (including complete i-circRNAs and 
partial i-circRNAs). 
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2.3 Interior circRNA predominantly expressed in nascent RNA   
It was unexpected and surprising that i-circRNAs expressed predominantly in nascent (newly-
transcribed) RNA (Figure 6). We found that more than 50% of the total detected circRNAs were 
i-circRNAs without splicing signals (Figure 6A) by applying the CAT method to a non-stranded 
Ribominus RNA-seq dataset (Figure 6B). These results from the three cancer cell lines that we 
considered and from the first 120 minutes when nascent RNAs were profiled [77] were consistent 
(Figure 6A).  
 
Figure 6. Distribution of circRNAs in nascent RNA. (A) Distribution of circRNAs in different time points 
of three cell lines, PA1, H9, and FB, sequenced from non-stranded and Ribominus libraries. (B) The number 
of samples for each time point in the non-stranded nascent RNA dataset GSE73325. (C) Distribution of 
circRNAs in three stranded Ribominus cancer cell lines, HeLa, Caki2 and A549, and three-time points of 
non-stranded RNase R treated libraries of PA1. All circRNAs are annotated as to whether being adjacent 
to splicing signals or not. The total number of circRNAs detected for each dataset, including boundary and 
interior circRNAs after classification, are indicated below the name of the dataset.  
Interestingly, the expression of circRNAs, particularly i-circRNAs, was transient in nascent RNA. 
During the period of nascent RNA profiling, only a small percentage of circRNAs persisted from 
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one time-point to the next, indicating a high turn-around rate of circRNA. To confirm the validity 
of the transient circRNAs in nascent RNAs, we also used RNase R treated RNA-seq data of PA1 
(Figure 6B). This set of data covered three time-points that matched the RNA-seq dataset from the 
ribosome depletion protocol. The interior and canonical circRNAs from the RNase R treated 
dataset had similar expression patterns (Figure 6C) as that from the ribosome-depletion dataset 
(Figure 6A), i.e., ~90% of the detected circRNAs, were not associated with splicing signals.  
To further validate that interior circRNA predominantly expressed in nascent RNAs, we also 
studied the stranded ribo-minus RNA-seq data from three cancer cell lines (GSE92250), HeLa 
(cervical cancer), A549 (lung carcinoma), and Caki2 (epithelial carcinoma of the kidney) [78]. 
Similar expression patterns were also observed in these cancer cells (Figure 6C). It is important to 
highlight that the RNA-seq data for these three cancer cell lines were collected at the M phase of 




Chapter 3. Characteristics of circular and chimeric RNA 
Recent genome-wide sequencing-based RNA profiling has revealed properties and potential 
functions of some circRNAs and chimeric RNAs, but the characteristics and functions of most 
circRNAs and chimeric RNAs are still elusive. Here, we analyze circRNAs and chimeric RNAs 
identified by CAT and study their characteristics, particularly the characteristics of interior 
circRNAs and interior chimeric RNAs.  
3.1 Characteristics of circRNA 
Some characteristics of circRNAs have been investigated and validated so far. For example, 
circRNAs are stable in cells, especially most circRNAs from exons exhibit a half-life more than 
48h [35]; expressions of circRNAs are specific to cell types and tissues [16-21] as well as 
developmental stages and ages [17, 22]; evolutionarily conserved sequences of circRNAs have 
been found between human and mouse. Analyzing circRNAs detected from five datasets of 
humans and Arabidopsis (Table 4), we have found three new characteristics of canonical circRNAs 
and i-circRNAs, i.e., many circRNAs are associated with short homologous sequences, some 
circRNAs are flanked by complementary sequences, and more than one circRNA may originate 
from the same genomic locus. 
3.1.1 Short homologous sequences associated with circRNAs 
One interesting finding of circRNAs was short homologous sequences (SHSs) at the back fusion 
points of canonical circRNAs and i-circRNAs (Figure 7A). The lengths of SHS vary from 1- to 
45-nt with the majority in the range of 1- to 6-nt and peaked at 1-nt, 2-nt or 5-nt (Figure 7B). SHSs 
are overall abundant, with the percentage of circRNAs with SHSs ranging from 45.3% (315 out of 
695 in HeLa) to 97.8% (45 out of 46 in the liver) and the abundance is more pronounced in i-




Figure 7. Sequence and structural features characteristic of i-circRNAs. (A) An example of the effect of 
SHS on possible back fusion points on i-circRNA hsa_circ_0092624, where due to dinucleotides GA and 
sequencing reads across GA, there may exist three candidate back fusion points, marked as 1, 2 and 3. (B) 
Distribution of canonical and interior circRNAs with SHSs of different lengths in 5 tissues and cell types 
in human and Arabidopsis. (C) Distribution of SHS in i-circRNAs detected from the five datasets. (D) An 
example of RNA folding structure and complementary sequences flanking an intronic i-circRNA, 
hsa_circ_0092998. 
3.1.2 Complementary sequences flanking circRNAs 
RNA folding structures over the flanking sequences near the back splicing or back fusion points 
of circRNAs constitute constructs for the production of some canonical circRNAs [43-47]. To test 
if this is also the case for some of the i-circRNAs identified, we fold the 100-bp sequences up- and 
down-stream of the back fusion points of canonical and interior circRNAs with RNAfold [79]. For 
each circRNA, 100-nt sequences outside of the 5’-end and 3’-end of the back fusion point are 
extracted separately. The two sequences are concatenated together in the 5’- to 3’-end order, and 
RNAfold [79] is then applied to the concatenated sequence to find the secondary structure of the 
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merged sequence with the minimum free energy. The secondary structure is divided into two equal 
parts from the center. The two parts are filtered with the following criteria: 1) at least 50-nt (i.e., 
50% of the 100-nt sequence) are paired with nucleotides from the other part, and 2) no more than 
10-nt are paired with nucleotides from the same part. The sequences passing through these criteria 
are considered to have complementary structures that may favor the generation of circRNAs. A 
total of 26 (4.1% of 641), 44 (6.6% of 664), 13 (4.3% of 304), 4 (4.6% of 87), and 7 (21.9% of 32) 
i-circRNAs (k=5) in HeLa, prostate, Arabidopsis, brain, and liver, respectively, have paired 
flanking sequences (see Figure 7D for an example). This suggested that some i-circRNAs might 
be generated through fold-back structures of complementary sequences. 
3.1.3 More than one interior circRNA from the same genomic locus 
Our results also revealed that more than one i-circRNA may originate from inside of the same 
intron or exon for the two species we analyzed (Figure 8A). Interestingly, one transcript may even 
host multiple circRNAs, some of which share some common sequences. Specifically, 534 (52.5%), 
57 (6.8%), 6 (13.3%), 3 (6.5%) and 21 (47.7%) of all circRNA generating transcripts may produce 
more than one circRNA in HeLa cells, human prostate cancer cells, Arabidopsis inflorescences, 
human brain, and human liver, respectively (Figure 8A). For example, four i-circRNAs emerge 
from the locus of the first exon of gene RMRP in the HeLa cells, and the exon itself produces a 
canonical circRNA hsa_circ_0092379 (Figures 8B-D). The largest i-circRNA from this locus, 
hsa_circ_0092379_i1, spans across the 5’UTR and the first exon of RMRP (Figure 8C). This i-
circRNA (hsa_circ_0092379_i1) and the circRNA from the first exon were identified by RNA-
seq profiling experiments, and the i-circRNA was also detected by the Sanger sequencing, even 
though its expression level was relatively lower than the canonical circRNA. The Sanger 
sequencing detected three additional smaller i-circRNAs, all of which are embedded within the 
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largest i-circRNA (Figure 8D). The smallest i-circRNA (i.e., hsa_circ_0092379_i4) also resides 
completely inside the other two i-circRNAs (hsa_circ_0092379_i2 and has_circ_0092379_i3, 
Figure 8D).  
 
Figure 8. Multiple i-circRNAs from the same genomic locus. (A) Distributions of multiple and single i-
circRNAs originated within a single exon or intron in the HeLa cells, prostate cancer cell lines, Arabidopsis 
inflorescences, human normal brain and liver tissues when the minimal number of supporting reads in at 
least one sample is set to k = 5. (B) Detection of multiple i-circRNAs around the locus of the first exon of 
gene RMRP in the HeLa cells by PCR. The divergent and convergent arrows above the gel image represent 
divergent and convergent PCR primers used, respectively, and the white arrows in the gel image indicate 
detected i-circRNAs. Gene GRAPDH is used as an internal control. (C) The genomic origin of the largest 
i-circRNA hsa_circ_0092379-i1, its circular structure, the results from RNA-seq (the four lines of 
sequencing reads on the top left) and the Sanger sequencing (on the lower right). The two back fusion points 
of this circRNA are 2-nt before the exon and 1-nt before the end of the exon. Included here is the RNA-seq 
result of the canonical circRNA hsa_circ_0092379 from the exon (the four lines of reads on the top right). 
(D) The genomic origins of three smaller i-circRNAs hsa_circ_0092379_i2, _i3 and _i4, their circular 
structures, back-fusion points and the results from the Sanger sequencing. All of these i-circRNAs reside 
within the largest i-circRNA hsa_circ_0092379-i1 shown in (C). 
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Note that some i-circRNAs were not initially detected by RNA-seq profiling, but rather by 
subsequent PCR and/or the Sanger sequencing. For example, the back-fusion points of the three 
smaller i-circRNAs hsa_circ_0092379_i2 to hsa_circ_0092379_i4 (Figure 8D) were not recorded 
in the RNA-seq data but instead were serendipitously discovered by PCR using the same pairs of 
divergent primers designed to validate their companion canonical circRNA, hsa_circ_0092379, 
and the largest i-circRNA, hsa_circ_0092379_i1.  
3.2 Characteristics of chimeric RNAs 
Chimeric RNAs were analyzed based on the genomic loci of their fusion junctions and host genes. 
In addition to splicing signals, short homologous sequences were also found at the fusion junctions 
of most chimeric RNAs. For the same pair of host genes, more than one chimeric RNA may be 
generated by different combinations of exons and introns. 
3.2.1 Short homologous sequences associated with chimeric RNAs 
Short homologous sequences (SHSs) have been identified to associate with circRNAs (see Chapter 
2). In chimeric RNAs, we also observed the existence of short homologous sequences overlapping 
with the fusion points, which may facilitate the formation of chimeric RNAs. In the tumor, normal, 
PP and NN dataset (Table 3), 2288 (88.5% of the total), 2213 (88.2%), 1176 (90.5%), and 1432 
(90.8%) of the chimeric RNAs that we identified were associated with short homologous 
sequences (Figure 9A). Interestingly, not only chimeric RNAs without splicing signals but also 
most chimeric RNAs with splicing signals were detected to have short homologous sequences, 
indicating a facilitating role that SHSs may play in the formation of chimeric RNAs.  
3.2.2 More than one chimeric RNA from the same genomic locus 
Another property of chimeric RNAs is that more than one chimeric RNA may be generated from 
the same genomic locus. In tumor, normal, PP and NN, 117, 106, 78, and 94 host genes produced 
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more than one chimeric RNA, i.e., 293, 251, 178, and 218 chimeric RNAs, respectively (Figure 
9B). Moreover, a well-known chimeric RNA in prostate cancer, TMPRSS2-ERG [56, 80, 81], also 
has multiple alternative chimeric transcripts in our tumor data (Figure 9C). The junctions of 
chimeric RNAs from TMPRSS2-ERG may be combinations of exon-exon, intron-intron, or even 
antisense of exon and intron, suggesting the complexity and diversity of fusion structures. Note 
that SHSs are also observed in five of the six examples, further confirming the involvement of 
SHSs in the formation of chimeric RNAs. 
 
Figure 9. Sequence and structural characteristics of chimeric RNAs. (A) SHS distribution of chimeric 
RNAs in the datasets of tumor, normal, PP and NN when the number of supporting reads in at least one 
sample is set as k = 5. (B) Distribution of host gene pairs with single or multiple chimeric RNAs. (C) An 
example of multiple chimeric RNAs originating from the same pair of genes, TMPRSS2 and ERG. Black 
sequences overlap the fusion points of chimeric RNAs, while blue and orange sequences are from the 
corresponding 5’ host and 3’ host genes, respectively. Splicing signals are underlined and SHSs are 
indicated with asterisks.   
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Chapter 4. Functions of circular and chimeric RNAs 
Various functions have been studied for both circular and chimeric RNAs in cancer [23, 58, 66]. 
In this study, we focused on autoimmune disease, psoriasis, which has not been well studied for 
circular and chimeric RNAs. Our results revealed that circRNAs may function as competing 
endogenous RNAs and chimeric RNAs may compete with their host genes in psoriatic skin.  
4.1 circRNAs function as competing endogenous RNAs in psoriatic skin 
Psoriasis (PS) is a chronic, inflammatory, and immune-mediated skin disease, characterized by 
raised, red scaly plaques [82]. Its prevalence ranges from 0.09% to 11.4%, affecting at least 100 
million individuals worldwide [83]. Besides the long-lasting and high recurrence rate, PS may 
increase the risk of stroke [84], myocardial infarction [85], type 2 diabetes [86], and cancer [87, 
88]. The etiology and pathogenesis of PS remain poorly understood. Studies in the past decades 
have identified many genetic risk factors [89, 90] and aberrant expression of many transcripts, 
including non-coding RNAs such as microRNAs (miRNAs) [91-94] and long non-coding RNAs 
(lncRNAs) [95]. The expression of many PS related mRNAs may be regulated by miRNAs [93, 
94]. For example, miR-21 contributes to T-cell derived psoriatic skin inflammation [96], and 
overexpression of miR-31 enhances the production of inflammatory cytokines and chemokines 
[97]. Many lncRNAs also function in PS, e.g., PRINS [98, 99], lnc-IL7R [100], and LincR-Ccr2-
5′AS [101]. 
However, the expression and potential function of circRNAs in PS are understudied and poorly 
understood and only three studies have been described so far. A microarray-based analysis of 
psoriatic lesions identified 4,956 differentially expressed (DE) circRNAs [102], a study of 
mesenchymal stem cells (MSC) of psoriatic skin described 129 DE circRNAs [103], and a recent 
study of six paired lesional and non-lesional skin samples reported 148 DE circRNAs [104]. The 
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microarray study missed novel circRNAs, the MSC study was unlikely to have captured many 
circRNAs of psoriatic skin, and the skin study only compared circRNAs between lesional and non-
lesional skin but not those of healthy controls. 
We set forth to identify novel circRNAs and study their potential functions in PS. We studied a 
cohort of 93 skin tissue samples (GSE121212) from which a large collection of circRNA-enriched 
RNA-seq libraries from 28 psoriatic-involved (PP) lesions, 38 normal (NN) controls, and 27 
psoriatic-uninvolved (PN) skin samples were derived. Besides studying circRNAs arising from 
intron-exon boundaries, we also studied i-circRNAs arising from the interior regions of introns, 
exons, and intergenic regions [105]. We confirmed our discoveries with three validation sets of 
RNA-seq data from psoriatic samples and cell lines. We also experimentally validated and studied 
three circRNAs in psoriatic skin with RT-PCR and Sanger sequencing. Furthermore, we studied 
the potential function of circRNAs as competing-endogenous RNAs (ceRNAs) in PS.  
4.1.1 circRNAs in psoriatic skin 
Four paired-end RNA-seq datasets from human skin were used to investigate circRNAs in PS.  
One was used for discovery, the other three were used for validation. The discovery dataset, 
hsa_skin1 (GSE121212), was derived from human skin biopsies where the TruSeq Stranded Total 
RNA Protocol was used in combination with the RiboZero rRNA removal Kit. It consisted of 28 
PP, 38 NN, and 27 PN samples. One of the validation datasets, hsa_skin2 (GSE74697), was 
generated from human skin samples with the ScriptSeq complete kit from Epicenter and contained 
18 PP and 16 NN samples. The other two datasets, hsa_MSC1 (GSE81106) and hsa_MSC2 
(GSE89725), were from skin-derived Mesenchymal stem cells (MSC) and derived with the TruSeq 
Stranded Total RNA Library Prep kit using the CircRNA Enrichment kit and ribo-zero rRNA 
Removal Kit, respectively. Each of the MSC datasets consisted of 3 PP and 3 NN samples. 
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Figure 10. Distribution and characteristics of abundant circRNAs in PS. (A) Names and number of samples 
in the discovery and validation datasets. In total, 179 abundant circRNAs were identified in the discovery 
dataset, among which 166, 83, and 51 were independently validated by the three validation datasets. (B) 
Distribution of the 179 circRNAs in the discovery dataset. All circRNAs are annotated as to whether they 
are adjacent to splicing signals. (C) An example of RNA folding structure and complementary sequences 
flanking an exon i-circRNA, hsa_skin_038904. (D) Distribution of the lengths of short homologous 
sequences (SHS) in the discovery dataset. (E) An example of two circRNAs, hsa_skin_175896 and 
hsa_skin_226345, arising from gene FLG (Filaggrin). (F) Average expression (spliced reads per billion 
mappings [SRPBM]) of the 179 highly expressed circRNAs in PP and NN skin. (G) Volcano plot 
visualizing differential expression of circRNAs when PP and NN skin samples were compared. The red 
and black dots in the plot represent significantly differentially expressed (p-value < 0.01) and not 
significantly expressed circRNAs, respectively. Circle and cross marks represent interior and boundary 
circRNAs (canonical circRNAs), respectively. 
From the discovery dataset, we identified 179 circRNAs expressed in at least 10 samples and 
supported by at least 5 reads in one of these samples. Among the 179 circRNAs, 64 (35.8%) were 
identified for the first time and 65 (36.3%) were i-circRNAs, 49 of which were novel. As a 
validation of the result, we examined the expression of the 179 circRNAs in the three validation 
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RNA-seq datasets (Figure 10A). In total, 170 circRNAs were expressed in at least one of the three 
validation datasets. In particular, 166 (92.7%) of the 179 circRNAs were expressed in another 
large RNA-seq dataset hsa_skin2 of 34 psoriatic and normal skin biopsy samples, and 37 circRNAs 
were highly expressed in all three validation datasets (Figure 10A). Among these, three were exon 
or intron i-circRNAs with no associated splicing signal. A substantial portion of the canonical and 
partial i-circRNAs, but very few of the complete i-circRNAs, of the 179 circRNAs carried the 
splicing signal (Figure 10B). 
Not surprisingly, many circRNAs exhibit the three characteristics that we have revealed in Section 
3.1. First, they have complementary sequences flanking their BF points; 24 circRNAs had paired 
flanking sequences, among which 17 were i-circRNAs including 15 with no splicing signal (see 
Figure 10C for an example). This suggested that the production of these i-circRNAs may be 
assisted by fold-back structures of complementary sequences. Second, the BF points of many 
circRNAs, particularly i-circRNAs, resided within short homologous sequences (SHSs), with 
lengths of 1- to 56-nt and peaked at 2-nt (Figure 10D). Among the 179 abundant circRNAs, 101 
(56.4%) were associated with SHS that were longer than 2-nt, 29 of which had no splicing signal, 
indicating a potential role of SHS in circRNA biogenesis. Third, more than one circRNA may arise 
from a genomic locus. Among the 161 host genes of the 179 circRNAs, 13 (including FLG, FLG2, 
KRT10, KRT2, and LPP) produced multiple circRNAs. For example, hsa_skin_175896 contained 
hsa_skin_226345 (Figure 10E).  
4.1.2 Aberrantly expressed circRNAs in PS 
Two criteria were introduced to identify abundantly expressed circRNAs. First, the minimal 
number of reads mapped to a BF point in at least one sample is no less than k=5. Second, the total 
number of samples in which the circRNA appears is no less than m, a parameter is adjusted for 
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different sample sizes; in our experiment, m=10. The circRNAs that did not meet these two criteria 
were considered as having low expression. The expression levels of highly expressed circRNAs 
were normalized by SRPBM (spliced reads per billion mappings), i.e., the number of circular 
reads/number of mapped reads (units in billion), to ameliorate the effects of sequencing depth and 
batch effects. Differentially expressed (DE) circRNAs were identified by the RankSum method 
[106] with a threshold of p-value ≤ 0.01 based on SPRBM. DE genes of PP versus NN and PN 
were obtained with the Tophat and Cufflinks pipelines [107], with the threshold being adjusted to 
q < 0.05 and fold change > 2. Using SRPBM, 47 (26.3%) of the 179 circRNAs were expressed at 
higher levels between PP vs. NN (Figure 10F) and 51 (28.5%) circRNAs were differentially 
expressed (DE) in PP vs. NN skin (Figure 10G, see Appendix).  
A putative function of circRNAs is acting as competing-endogenous RNAs (ceRNAs) [108] for 
regulating mRNA genes that share common regulating miRNAs with circRNAs. We named these 
circRNAs ce-circRNAs and the associated mRNAs circRNA-associated genes. More precisely, 
circRNA-associated mRNAs were defined as DE mRNAs that were positively regulated by 
circRNAs via circRNA-miRNA-mRNA regulatory cascades. That is, a DE mRNA was associated 
with a circRNA if both were bound and regulated by a common miRNA. mRNA and circRNA 
targets of mature miRNAs [109] were predicted with miRanda [110] using the default parameters 
of a score of 140.0 and energy of -1.0. CircRNA-associated genes were selected from the DE genes 
that were positively correlated with their corresponding circRNAs, i.e., Spearman’s rank 
correlation coefficient > 0.0 and p-value < 0.01. In total, there existed 8,096 mRNA genes 
significantly DE between PP vs. NN skin, among which 4,034 were associated with 51 DE 
circRNAs.  
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Figure 11. Experimental validation of three identified circRNAs in psoriatic skin and HaCaT keratinocyte 
cells. (A) Validation of a well-known intergenic i-circRNA (CDR1as), a novel exon i-circRNA 
(hsa_skin_052271), and a canonical circRNA (hsa_skin_088763) by PCR. The divergent and convergent 
arrows above the gel image represent, respectively, the divergent and convergent PCR primers used in RNA 
(cDNA) and DNA (gDNA), and the white arrows in the gel image point to circRNAs. Numbers on the left 
ranging from 100 to 1kb+ represent sizes in DNA ladder. GAPDH was used as an internal control. (B) 
Validation of CDR1as, hsa_skin_052271, and hsa_skin_088763 by Sanger sequencing. (C) Box and 
whisker plot for RNase R validation of differential expression of CDR1as, hsa_skin_052271, and 
hsa_skin_088763 when PP vs. PN skin was compared. (D) Quantitative real-time PCR (qRT-PCR) 
validation of differentially expressed circRNAs CDR1as, hsa_skin_052271, and hsa_skin_088763 in PP 
vs. PN skin. (E) RNA-seq (hsa_skin2 of validation set) validation of differentially expressed circRNAs 
CDR1as, hsa_skin_052271, and hsa_skin_088763 in PP vs. NN skin.  
From these circRNAs, we selected two canonical circRNAs, hsa_skin_194345 (CDR1as) and 
hsa_skin_088763 (hsa_circ_0109327), and three i-circRNAs, hsa_skin_100269, 
hsa_skin_143837, and hsa_skin_052271 for experimental validation using psoriatic skin biopsy 
samples (PP and PN) and HaCaT keratinocyte cells. Using sequencing reads across BF points as 
surrogates to circRNAs, the five circRNAs had 1440, 405, 41, 24, and 22 reads in the discovery 
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dataset, respectively. Note that these five circRNAs were all detected in the validation datasets, 
providing the first validation of these circRNAs in psoriasis. For experimental validation, 
divergent and convergent PCR primers were applied separately to the RNA and DNA of these 
circRNAs. Three circRNAs, CDR1as, hsa_skin_052271, and hsa_skin_088763, were 
experimentally validated (Figure 11A) and their BF points were confirmed with Sanger sequencing 
(Figure 11B). Sanger sequencing successfully recovered the full-length of hsa_skin_052271. 
Furthermore, the three validated circRNAs were subjected to RNase R treatment, and the changes 
in their expression in PP vs. PN were confirmed. The fold changes from the RNase R experiments 
were consistent with and even more pronounced than that of the untreated ones (Figure 11C). qRT- 
PCR was also applied to validate their RNA-seq based DE in PP vs. PN skin and consistent fold 
change directions were confirmed (Figure 11D). We also determined that these circRNAs were 
DE in PP vs. NN skin by an analysis of sequencing data from the hsa_skin2 validation dataset 
(Figure 11E). 
4.1.3 Putative circRNA functions in PS 
The three experimentally validated circRNAs may potentially function as ce-circRNAs in psoriatic 
skin. CDR1as may regulate 149 out of 655 targets of miR-7-5p via 67 binding sites and 242 out of 
962 targets of miR-135b-5p via 4 binding sites (Figure 12A). CDR1as was sharply down-regulated 
3.7 fold between PP vs. NN, whereas both miR-7-5p and miR-135b-5p were up-regulated in 
psoriasis [91, 94, 111]. The target genes that were down-regulated in PP skin and positively 
correlated with the expression of CDR1as by Spearman’s rank-order correlation analysis were 
called circRNA-associated genes of CDR1as (Figure 12A). Among the associated genes were 
EGR3, GATA6, GATA3, and FOXN3, which play important roles in psoriasis. EGR3 can regulate 
late epidermal differentiation and contribute to the keratinocyte differentiation-related module in 
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a skin-specific network [112]. GATA6 has significantly lower expression in psoriatic dermal MSCs 
[113]. FOXN3, regulating cell differentiation and cell cycle, is down-regulated along with GATA3 
in psoriasis [114]. 
CircRNA hsa_skin_088763 from pseudogene RP11-255H23.2 may regulate 109 out of 560 targets 
of miR-338-3p via 4 binding sites and 340 out of 1508 targets of miR-23a/b-3p via 10/11 binding 
sites (Figure 12B).  hsa_skin_088763 was down-regulated 2.6 fold when PP vs. NN was compared, 
and miR-338-3p and miR-23a/b-3p were up-regulated in psoriasis, consistent with this trend in 
their putative regulatory circRNA [115]. Several psoriasis-related genes were among the 
associated genes of hsa_skin_088763, including GATA6, SIK2 (Figure 12B), IL17RD [116], 
EGR3, FAS, LRIG1, and PPARGC1A [117]. LRIG1 negatively regulates growth factor signaling 
to regulate epidermal stem cell quiescence [118]; SIK2 modulates cytokine responses during innate 
immune activation [119]; FAS signaling is essential for inducing key inflammatory cytokines in 
psoriasis [120]. All these results indicated that hsa_skin_088763 functions as a ceRNA in psoriasis. 
hsa_skin_052271, an i-circRNA from the third exon of gene FLG2, may mediate three target genes 
of miR-135b-5p, two target genes of miR-205-5p, and nine target genes of miR-27a-3p (Figure 
12C). hsa_skin_052271 was down-regulated 2.8 fold between PP and NN, and miR-135b-5p [91, 
94, 111], miR-205-5p [91] and miR-27a-3p [115] were up-regulated in psoriasis. Psoriasis-related 






Figure 12. Putative functions of three circRNAs as ceRNAs. The genomic origin of (A) intergenic i-
circRNA CDR1as, (B) exon boundary circRNA hsa_skin_088763, and (C) exon i-circRNA 
hsa_skin_052271, their psoriasis-related binding miRNAs predicted by miRanda, and their circRNA-
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associated genes. Volcano plots visualize the differential expression of target genes between PP and NN 
skin. The red and black dots in the plot represent significantly down-regulated (p-value < 0.01) and other 
target genes, respectively. Among the significantly down-regulated target genes, those that are positively 
correlated with the expression of circRNAs are defined as circRNA-associated genes. Scatter plots show 
Spearman’s rank-order correlation between three circRNAs and one of their associated genes, where r is 
the Spearman correlation coefficient. 
4.2 Potential functions of chimeric RNAs in prostate cancer and psoriasis 
Some chimeric RNAs and their encoded proteins have been taken as biomarkers and therapeutic 
targets of many cancers over the past decade [55, 63], which have often focused on cancer cells 
but failed to investigate the corresponding non-diseased cells. Recent research has also shown the 
existence of chimeric RNAs in non-cancerous cells and tissues [64, 121]. Here, we applied CAT 
to identify chimeric RNAs from four datasets of stranded RNA-seq in cancerous and normal 
prostate tissues, and psoriatic and normal skins (Table 3). 
In total, we detected 2585, 2509, 1299, and 1577 chimeric RNAs in the tumor, normal, PP, and 
NN dataset, respectively. The host genes, i.e., genes overlapping with chimeric RNAs, were 
analyzed by Metascape [122] and the top 20 enriched pathways were listed for each tissue (Figure 
13). In the prostate, cancer and normal cells shared several tissue-specific pathways, such as “lipid 
oxidation” and “membrane trafficking”. Moreover, the host genes of cancer cells were enriched 
for some cancer-related pathways, for example, “modification-dependent protein catabolic 
process”, “histone modification”, “autophagy”, “signal transduction by p53 class mediator” and 
“signaling by NOTCH1 PEST domain mutants in cancer” (Figure 13A). In psoriasis, the common 
enriched pathways of lesional and non-lesional tissues were skin-specific, such as “epidermis 
development” and “regulation of epidermis development”. Furthermore, several psoriasis-related 
pathways were enriched by host genes of lesional skins, e.g., “deubiquitination”, “regulation of 
water loss via skin”, “activation of the innate immune response” and “myeloid leukocyte mediated 




Figure 13. Pathways enriched by host genes of chimeric RNAs. Top 20 GO terms and pathways enriched 
by host genes of chimeric RNAs identified in (A) tumor and normal tissues of prostate and (B) in PP and 
NN samples of skin. Disease-associated pathways are underlined in red.  
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The total numbers of chimeric RNAs detected in tumor and normal tissues were comparable, but 
a good portion of chimeric RNAs was state specific, i.e., 1239 (47.9% of 2585) and 1163 (46.4% 
of 2509) were identified only in the tumor and normal tissues, respectively (Figure 14A). Similar 
results were also observed in psoriasis, namely, 645 (49.7% of 1299) and 923 (58.5% of 1577) 
chimeric RNAs were specific to PP and NN, respectively (Figure 14B).  
 
Figure 14. Differentially expressed chimeric RNAs. Venn diagrams show the number of chimeric RNAs 
identified in (A) tumor vs. normal, and (B) PP vs. NN.  Differentially expressed chimeric RNAs (C) 
between tumor and normal tissues in prostate and (D) between PP and NN in skin. Chimeric RNAs with 
fold change > 2 and p-value < 0.01 were defined as significantly differentially expressed chimeric RNAs.  
To better understand the functions of chimeric RNAs in prostate cancer and psoriasis, differential 
expression of chimeric RNAs that were expressed in at least 30 samples was analyzed by the 
Wilcoxon Rank Sum test [106]. Chimeric RNAs with differential expression greater than 2 folds 
and p-value < 0.01 were defined as significantly differentially expressed chimeric RNAs. Not 
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surprisingly, 23 chimeric RNAs were up-regulated between prostate cancer and normal tissues, 
whereas 26 were down-regulated (Figure 14C, see Appendix), and 34 chimeric RNAs were up-
regulated between lesional and non-lesional skin, whereas 39 were down-regulated (Figure 14D, 
see Appendix), indicating potential functions of chimeric RNAs in prostate cancer and psoriasis.  
In the prostate, the most significantly up-regulated chimeric RNA was an isoform of TMPRSS2-
ERG (Figure 9C1) that concatenated the first exon of TMPRSS2 with the second exon of ERG. It 
was sharply up-regulated 44.7 fold between tumor and normal tissues with p-value < 0.0001. 
Pathways of “nucleobase-containing compound transport” and “protein processing” were enriched 
by the host genes of up-regulated chimeric RNAs, while cancer-related pathways “ER to Golgi 
Anterograde Transport” and “Transcriptional misregulation in cancer” were enriched by the host 
genes of down-regulated chimeric RNAs (Figure 15A). This indicated that expression of chimeric 
RNAs may compete with the expression of their host genes, i.e., chimeric RNAs were lowly 
expressed in cancer when their cancer-related host genes were highly abundant in tumor tissues. 
In psoriasis, analysis of the host genes of these DE chimeric RNAs revealed two and three enriched 
pathways for up-regulated and down-regulated chimeric RNAs, respectively (Figure 15B). Note 
that psoriasis-related pathways “skin development” and “regulation of Wnt signaling pathway” 
were enriched by the host genes of down-regulated chimeric RNAs. Moreover, among the 45 host 
genes of down-regulated chimeric RNAs, 14 genes (31.3%) were significantly up-regualted in PP 
vs. NN, confirming our hypothesis that the expression of these chimeric RNAs may compete with 
their host genes. The most significant down-regulated chimeric RNA was a novel 
interchromosomal chimeric RNA, PDE6A-RMRP, which joined the antisense of the interior region 
of intron 17/19 of PDE6A on chromosome 5 to the interior of exon 1 of RMRP on chromosome 9 
(Figure 15C). More importantly, it was not observed in PP but expressed in all 38 NN samples 
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with 6,883 supporting reads and 250 unique supporting reads in total, and a 2-nt short homologous 
sequence was adjacent to the fusion point. Furthermore, one of the host genes, RMRP [123], is a 
long non-coding RNA (lncRNA) that regulates Th17 cells, which are important in the pathogenesis 
of psoriasis [124]. All these results suggest that this novel interior chimeric RNA, PDE6A-RMRP, 
may function in psoriasis and may be taken as a potential biomarker in psoriasis.  
 
Figure 15. Pathways enriched by host genes of DE chimeric RNAs. Pathways enriched by host genes of 
up-regulated and down-regulated chimeric RNAs between (A) tumor and normal, and between (B) PP and 
NN. Disease related pathways were underlined in red. (C) A novel interchromosomal chimeric RNA 
identified in NN, PDE6A-RMRP, which joined the antisense of the interior region of intron 17/19 of gene 
PDE6A on chromosome 5 to the interior of exon 1 of gene RMRP on chromosome 9. A short homologous 
sequence of  “AA” was observed at the fusion point, which was indicated with red asterisks. 
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Chapter 5. Biogenesis models and summary 
Splicing is known to be a model of biogenesis for the production of messenger RNAs (mRNA), 
which removes introns and joins exons in the process. For circular and chimeric RNAs, back-
splicing and trans-splicing are also established models of biogenesis. However, the discovery of 
the interior circular and chimeric RNAs was intriguing and shed new light on the biogenesis of 
these two types of non-co-linear RNAs. The short homologous sequences (SHSs) that we 
discovered in the fusion conjunctions of circular and chimeric RNAs may be a critical element of 
the underlying biogenesis models for circular and chimeric RNAs. 
5.1 A splicesome-independent mechanism for circular and chimeric RNA 
production 
Not replying on splicing signals was our new CAT method able to detect candidate circRNAs and 
chimeric RNAs that exist in all regions of the genome, especially interior regions of introns, exons, 
and intergenic transcripts (Figures 4D and 5A). To understand how splicing influences the 
formation of circular and chimeric RNAs, we compared circular and chimeric RNAs with mRNAs 
detected in the dataset of prostate tumors (Table 3). The percentages of RNAs without splicing 
signals were quite different between these three types of RNAs, i.e., on average 0.14% of mRNAs 
were not associated with splicing signals, while the average percentages of RNAs without splicing 
signals for circular and chimeric RNAs were 49% and 84%, respectively (Figure 16A). Moreover, 
the splicesome-based biogenesis model cannot explain all canonical circRNAs. In particular, 
19,444 (21.05%) of the 92,369 circRNAs in the circBase [125] have no splicing signal adjacent to 
their back splicing points. This strongly suggested that a new mechanism other than splicing may 
exist and be responsible for the production of circular and chimeric RNAs that are not associated 
with splicing signals. 
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It was a big surprise to discover short homologous sequences (SHSs) at the fusion points of most 
circular and chimeric RNAs (Figures 7B, 9A, and 16B). This result was thought-provoking 
regarding the currently elusive mechanisms of their biogenesis. It has been well established that 
canonical circular and chimeric RNAs can be derived from canonical splicing sites [37, 38, 40]. 
On the other hand, there are pieces of evidence suggesting the existence of novel circRNA 
biogenesis pathways independent of the canonical splicing apparatus – blocking components of 
spliceosome in Drosophila melanogaster results in a higher ratio of circular RNAs to linear RNAs 
[126, 127]. The SHSs that we discovered may provide a missing piece to this puzzle. It is known 
that SHSs are involved in the production of some chimeric transcripts through template switching 
in RNA processing [128, 129]. It is then viable to hypothesize that template switching is involved 
in or responsible for the biogenesis of many circRNAs, particularly i-circRNAs. The complete i-
circRNA F-Circ2 from an oncogenic chimeric transcript in human discovered in an early study 
[130] provides direct evidence supporting this hypothesis. F-Circ2 arises from a chimeric 
transcript that fuses two genes PML and RARα [130]. Remarkably, our close examination of the 
sequence of F-Circ2 revealed that one of the fusion points of F-Circ2 resides within an SHS 
(GCTGCCAG) inside of two exons, which starts at the 32-nt from the 5’-end of the 4-th exon of 
PML and at the 88-nt from the 5’-end of the 4-th exon of RARα. Besides, the early results and our 
analysis also suggested that RNA fold-back structures due to inverse complementary sequences or 
RNA-binding proteins at the two ends of the fusion points of a circRNA can bring the two ends 
into a close neighborhood; subsequently, the SHSs at the back fusion points of the circRNA can 
trigger template switching, resulting in RNA circulation. In short, the results that we presented 
suggested one novel circRNA and chimeric RNA biogenesis pathway independent of the canonical 
splicing mechanism (Figure 16C). 
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Figure 16. Mechanisms of circular and chimeric RNAs. (A) Box plot for percentages of RNAs without 
splicing signals in chimeric RNAs, mRNAs, and circRNAs in prostate cancer. (B) Box plots showing 
percentages of SHS in chimeric RNAs, mRNAs, and circRNAs with or without splicing signals in prostate 
cancer. (C) Two possible circular RNA and chimeric RNA mechanisms, (left) splicing apparatus that uses 
splicing signal AG/GT for production of canonical circRNAs and chimeric RNAs, and (right) RNA 
template switching due to SHS to generate circular or chimeric transcripts.  
 
Although SHS is a very promising mechanism to generate circular and chimeric RNAs other than 
canonical splicing, there is a substantial portion of circular and chimeric RNAs whose production 
could not be explained by the existing models and the model that we suggested. For example, in 
the prostate tumor dataset, on average 24%, 20%, and 22% of chimeric RNAs, mRNAs, and 
circRNAs with splicing signals were associated with SHSs, respectively, and the averaged 
percentages were 10%, 35%, and 31% when there were no splicing signals (Figure 16B). This 
means that for chimeric RNAs without splicing signals, only ~10% could be generated by SHSs 
and the production for the remaining 90% could not be explained; for circRNAs without splicing 
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signals, ~30% may be formed by SHSs and the biogenesis for the other 70% circRNAs were still 
unknown. Therefore, multiple biogenesis mechanisms may co-exist for both circular and chimeric 
RNAs, and more future studies and experiments are needed to discover and validate novel 
mechanisms.  
5.2 Summary 
Although a few cases of circRNAs were reported decades ago, the recent genome-wide discovery 
of circRNAs as a ubiquitous form of RNA in eukaryotic organisms was surprising. The most 
important result that we discovered – interior circRNAs from interior regions of introns, exons, 
and intergenic transcripts – added a new member to the circRNA family. Utilizing our novel 
developed circRNA identification method CAT, we were able to detect candidate circRNAs that 
exist in all regions of the genome. Furthermore, in supporting and extending the early observation 
that circRNA may emerge from intergenic regions [7, 9, 49], we further recognized that circRNAs 
may arise from interior regions of intergenic transcripts. In short, our results showed that circRNAs 
could be produced from the interior of transcripts that have diverse genomic origins. 
It was unexpected to discover more i-circRNAs than canonical circRNAs residing over intron and 
exon junctions. It was also surprising to detect more than one i-circRNA from one genomic locus. 
It is interesting to note that additional multiple i-circRNAs can be identified by PCR followed by 
Sanger sequencing, which were initially missed by RNA-seq profiling. This must be primarily 
because RNA-seq profiling was often not sufficiently deep. It is critical to highlight that multiple 
i-circRNAs that we identified are different from multiple circRNAs from an ORF [131] because 
the latter are products of alternative splicing that contains different exons or introns.  
The success rate that complete i-circRNAs can be validated by PCR in HeLa cells is not high, at 
35.7% (5 out of 14), comparing to the 100% success rate on canonical circRNAs (2 out of 2). 
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Despite this relatively low success rate, the validation of the 5 complete i-circRNAs is sufficient to 
demonstrate that they are bona fide circRNAs, the central theme of the current study. Moreover, a 
complete i-circRNA has also been previously discovered by PCR from an oncogenic chimeric 
transcript fusing two genes PML and RARα [130]. In addition, we also identified i-circRNAs in 
human normal and psoriatic skin, and experimentally validated three of them using disease-related 
cell lines and PCR followed by Sanger sequencing. Combined, all these results showed that i-
circRNAs are not only genuine circRNAs, but also functional, particularly in diseases. 
Not surprisingly, using CAT we identified chimeric RNAs originating from interior regions of 
introns, exons, and intergenic transcripts, which constitute a great proportion of the population of 
chimeric RNAs in the cell. Besides, chimeric RNAs also exhibit the two features of circRNAs, i.e., 
short homologous sequences at the fusion points and more than one chimeric transcript from the 
same genomic locus. These similarities between chimeric RNAs and circRNAs may due to the 
similar non-co-linear structures and the possibility that many of them, particularly the interior 
circular and chimeric RNAs, are generated by the same or similar biogenesis machinery.  
We confirmed the expression and function of TMPRSS2-ERG in prostate cancer, which is the 
highest recurrent chimeric RNA [54]. More importantly, we discovered a novel interior chimeric 
RNA, PDE6A-RMRP, in human skins, which was associated with a 2-nt short homologous 
sequence but not any splicing signal. It was the most down-regulated chimeric RNA between 
psoriatic skin and normal skin – it was exclusively expressed in the normal skin. Furthermore, one 
of the host genes, RMRP [123], is a long non-coding RNA (lncRNA) that plays an important role 
in regulating the pathogenesis of psoriasis [124]. All these results suggest that the disappearance 
of this novel interior chimeric RNA, PDE6A-RMRP, in the psoriatic skin may serve as a potential 
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biomarker for psoriasis. Therefore, in addition to cancer, chimeric RNAs are also expressed in 
normal tissues and may be functional in immune-mediated diseases such as psoriasis.   
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CircRNAs differentially expressed between PP and NN skin in psoriasis 
name chrom start end strand type PP NN log2(PP/NN) p-value 
hsa_skin_176158 chr11 36227082-36227084 36227428-36227430 + 3' B 20.63 59.07 -1.52 0.005 
hsa_skin_017868 chr5 36982162-36982165 36986299-36986302 + 3' B 24.75 84.19 -1.77 0.005 
hsa_skin_173421 chr15 72045723-72045725 72046634-72046636 - 5' B 15.71 42.25 -1.43 0.004 
hsa_skin_102568 chr19 52383847-52383848 52385323-52385324 + 5' B 1.83 7.55 -2.05 0.005 
hsa_skin_137810 chr20 3218514-3218518 3218992-3218996 + 5' B 2.98 21.99 -2.88 0.000 
hsa_skin_028220 chr9 127444025-127444029 127445246-127445250 + 5' B 4.05 23.72 -2.55 0.002 
hsa_skin_050166 chr9 4860124-4860125 4860901-4860902 + 5' B 15.69 42.72 -1.44 0.006 
hsa_skin_039030 chr1 224189575-224189576 224190318-224190319 + B 13.12 103.15 -2.97 0.000 
hsa_skin_032293 chr10 45625950-45625951 45627105-45627106 - B 9.80 14.89 -0.60 0.000 
hsa_skin_006010 chr10 68644696-68644698 68647004-68647006 + B 7.48 30.19 -2.01 0.001 
hsa_skin_112375 chr11 92352094-92352096 92355403-92355405 + B 3.54 16.56 -2.22 0.001 
hsa_skin_150608 chr13 30630832-30630834 30631472-30631474 + B 3.26 14.96 -2.20 0.000 
hsa_skin_189139 chr17 73235473-73235476 73236993-73236996 + B 4.05 17.35 -2.10 0.005 
hsa_skin_192510 chr2 40428472 40430304 - B 92.49 275.52 -1.57 0.005 
hsa_skin_223866 chr22 32478979-32478980 32479274-32479275 + B 3.17 34.37 -3.44 0.000 
hsa_skin_059513 chr4 109462899-109462902 109463643-109463646 + B 4.13 12.13 -1.56 0.003 
hsa_skin_013327 chr5 73840477-73840481 73840758-73840762 + B 17.45 44.27 -1.34 0.005 
hsa_skin_130995 chr5 83537003-83537008 83542265-83542270 + B 16.07 54.42 -1.76 0.008 
hsa_skin_194732 chr8 38429681-38429684 38429948-38429951 - B 2.47 20.78 -3.07 0.000 
hsa_skin_194345 chrX 140783169-140783175 140784654-140784660 + I 23.57 310.97 -3.72 0.000 
hsa_skin_052271 chr1 152352401-152352423 152352626-152352648 - I 1.43 9.92 -2.79 0.000 
hsa_skin_194228 chr1 152354735-152354791 152354966-152355022 - I 6.83 26.73 -1.97 0.000 
hsa_skin_093700 chr1 152356347-152356353 152356497-152356503 - I 1.43 11.77 -3.04 0.000 
hsa_skin_098241 chr10 92450725-92450733 92451246-92451254 - I 15.60 25.64 -0.72 0.000 
hsa_skin_017093 chr17 39254341-39254346 39255167-39255172 - I 2.85 14.16 -2.31 0.004 
hsa_skin_088763 chr19 23831593-23831599 23833518-23833524 + B 21.83 129.55 -2.57 0.000 
hsa_skin_143837 chr2 113707872-113707876 113708437-113708441 - I 1.46 14.89 -3.35 0.001 
hsa_skin_142248 chr10 124942455-124942456 124943306-124943307 + 3' B 100.02 50.76 0.98 0.000 
hsa_skin_169953 chr17 7576810-7576812 7576950-7576952 + 3' B 30.30 37.90 -0.32 0.010 
hsa_skin_146560 chr16 16141172-16141173 16142942-16142943 + 5' B 27.17 12.48 1.12 0.000 
hsa_skin_214394 chr17 40818151-40818157 40818475-40818481 - 5' B 29.05 20.63 0.49 0.003 
hsa_skin_232176 chr7 139715928-139715933 139717012-139717017 - 5' B 36.79 14.87 1.31 0.000 
hsa_skin_026246 chr1 151315572-151315574 151316509-151316511 - B 40.16 30.11 0.42 0.001 
hsa_skin_153897 chr10 68959803-68959805 68960247-68960249 + B 77.69 33.06 1.23 0.000 
hsa_skin_183503 chr12 122340750-122340754 122341695-122341699 - B 181.70 141.33 0.36 0.005 
hsa_skin_216799 chr13 52397231-52397234 52398194-52398197 - B 37.60 6.77 2.47 0.000 
hsa_skin_199788 chr14 71587569-71587570 71589369-71589370 + B 53.33 14.32 1.90 0.000 
hsa_skin_213436 chr16 346146-346150 347105-347109 - B 25.78 12.18 1.08 0.000 
hsa_skin_192421 chr17 20204329-20204333 20205909-20205913 + B 71.48 28.28 1.34 0.000 
hsa_skin_203265 chr17 83084936-83084937 83085322-83085323 + B 61.75 24.55 1.33 0.000 
hsa_skin_083378 chr2 32414764-32414769 32416159-32416164 + B 27.21 17.12 0.67 0.000 
hsa_skin_050529 chr2 37316235-37316238 37317178-37317181 - B 204.16 144.49 0.50 0.006 
hsa_skin_083065 chr4 36228580-36228583 36229644-36229647 - B 680.04 415.55 0.71 0.001 
hsa_skin_189369 chr6 134028379-134028380 134029720-134029721 - B 18.41 11.27 0.71 0.002 
hsa_skin_171562 chr8 127890586-127890589 127890996-127890999 + B 37.36 17.79 1.07 0.000 
hsa_skin_156445 chr9 34241183-34241184 34242107-34242108 + B 8.79 2.43 1.85 0.000 
hsa_skin_228653 chr10 92450736-92450738 92451257-92451259 - I 5.71 1.82 1.65 0.000 
hsa_skin_006690 chr11 65499641-65499650 65499860-65499869 + I 13.62 11.38 0.26 0.008 
hsa_skin_228518 chr11 65504856-65504859 65505049-65505052 + I 10.72 5.15 1.06 0.002 
hsa_skin_060631 chr12 52645124-52645131 52645271-52645278 - I 12.85 4.19 1.62 0.002 
hsa_skin_130118 chr20 62276203-62276204 62276962-62276963 + I 12.98 9.89 0.39 0.001 
* type: Whether the candidate originated from annotation boundary. B:boundary, I: interior, 5' B: 5' boundary, 3' B: 3' boundary. PP: average 
expression level in PP. NN: average expression level in NN. log2(PP/NN): log2 fold change of PP vs. NN. 
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Chimeric RNAs differentially expressed between tumor and normal tissues in prostate 
cancer 
name PCa NN log2(PCa/NN)  p-value 
chr1:100017813-100017815_+|chr1:100049906-100049908_+ 1.55 0.50 1.63 0.01 
chr1:156286631-156286634_-|chr1:156279033-156279036_- 16.50 5.90 1.48 0.00 
chr1:168243067-168243069_+|chr1:168291157-168291159_+ 0.65 1.60 -1.30 0.00 
chr1:187418001-187418003_+|chr1:187443625-187443627_+ 0.85 2.15 -1.34 0.00 
chr1:205659275-205659277_-|chr1:205646805-205646807_- 0.50 3.25 -2.70 0.00 
chr1:205659488_-|chr1:205623891_- 8.90 34.25 -1.94 0.00 
chr1:222615822-222615825_+|chr1:222621155-222621158_+ 3.60 15.85 -2.14 0.00 
chr1:925516-925520_-|chr1:923460-923464_- 1.15 3.40 -1.56 0.00 
chr11:114450166-114450167_+|chr11:114466856-114466857_+ 3.85 0.95 2.02 0.00 
chr11:114517711-114517713_+|chr11:114526621-114526623_+ 6.20 1.20 2.37 0.00 
chr11:61582204-61582206_-|chr11:61556206-61556208_- 1.00 11.65 -3.54 0.00 
chr11:92225173-92225175_+|chr11:92352094-92352096_+ 2.60 8.15 -1.65 0.00 
chr11:92309823-92309826_+|chr11:92352093-92352096_+ 1.00 3.55 -1.83 0.01 
chr12:50456716-50456724_+|chr4:110523085-110523093_- 1.90 0.55 1.79 0.00 
chr13:31946178-31946181_+|chr13:32078830-32078833_+ 9.95 3.50 1.51 0.01 
chr13:95302064-95302066_+|chr13:95310833-95310835_+ 7.05 2.00 1.82 0.00 
chr15:69570902-69570904_+|chr15:69628736-69628738_+ 5.45 1.20 2.18 0.00 
chr15:69570902-69570904_+|chr15:69671723-69671725_+ 5.35 1.10 2.28 0.01 
chr15:81362035-81362036_+|chr15:81380207-81380208_+ 7.30 2.90 1.33 0.00 
chr17:3664678-3664680_-|chr17:3660326-3660328_- 0.95 2.40 -1.34 0.00 
chr17:58324624-58324627_+|chr17:58337444-58337447_+ 0.65 3.40 -2.39 0.00 
chr17:58518932-58518933_+|chr17:58525699-58525700_+ 0.25 1.55 -2.63 0.00 
chr19:50851337-50851340_+|chr19:50856237-50856240_+ 6.05 0.40 3.92 0.00 
chr2:20651488-20651490_-|chr2:20645504-20645506_- 1.50 3.40 -1.18 0.00 
chr2:210192801-210192803_-|chr2:210154609-210154611_- 1.30 3.20 -1.30 0.00 
chr2:218033819-218033822_-|chr2:217991056-217991059_- 2.40 9.35 -1.96 0.00 
chr20:59942509-59942513_+|chr20:59949250-59949254_+ 0.85 1.70 -1.00 0.00 
chr21:36698908-36698909_-|chr21:36643010-36643011_- 2.55 1.00 1.35 0.00 
chr21:41507948-41507952_-|chr21:38445620-38445624_- 13.40 0.30 5.48 0.00 
chr22:23527560-23527564_+|chr22:23536967-23536971_+ 1.55 3.15 -1.02 0.01 
chr3:52291108-52291111_+|chr3:52316451-52316454_+ 4.05 2.00 1.02 0.01 
chr3:53494417-53494419_+|chr3:53495044-53495046_+ 16.05 1.50 3.42 0.00 
chr4:164801513-164801514_+|chr4:164805605-164805606_+ 5.95 2.30 1.37 0.01 
chr4:169271607_-|chr4:169269307_- 3.35 0.75 2.16 0.00 
chr5:115634485-115634488_-|chr5:115625980-115625983_- 0.50 1.40 -1.49 0.01 
chr6:116060998-116060999_-|chr6:116060594-116060595_- 2.25 0.50 2.17 0.00 
chr6:44731367-44731368_+|chr6:44829586-44829587_+ 1.15 27.65 -4.59 0.00 
chr6:99175100-99175111_+|chr4:103086529-103086540_- 1.30 5.50 -2.08 0.00 
chr7:12094650-12094653_-|chr7:11636959-11636962_- 0.80 2.40 -1.58 0.00 
chr7:155003584-155003588_-|chr7:154998782-154998786_- 2.45 1.00 1.29 0.00 
chr7:156471152-156471154_-|chr7:156441378-156441380_- 7.20 0.60 3.58 0.00 
chr7:89882352-89882355_-|chr7:89694367-89694370_- 2.60 0.70 1.89 0.01 
chr7:99971745-99971746_-|chr7:99923603-99923604_- 6.75 15.30 -1.18 0.00 
chr9:111038649-111038654_-|chr9:110973556-110973561_- 0.80 2.30 -1.52 0.01 
chrX:119150934-119150936_-|chrX:119128059-119128061_- 0.60 2.90 -2.27 0.00 
chrX:119150936_-|chrX:119123652_- 1.45 3.10 -1.10 0.00 
chrX:125185641-125185644_-|chrX:124963816-124963819_- 1.25 4.50 -1.85 0.00 
chrX:71212920-71212926_+|chrX:71223688-71223694_+ 5.50 0.45 3.61 0.00 
chrY:12662525-12662528_-|chrY:12662124-12662127_- 2.80 1.20 1.22 0.01 
* name: name of chimeric RNAs are formed by their genomic loci, i.e., 5’-end junction|3’-end junction. PCa: average expression level in tumor 
tissue of prostate cancer (PCa). NN: average expression level in normal tiisues (NN). log2(PCa/NN): log2 fold change of PCa vs. NN. 
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Chimeric RNAs significantly up-regulated between PP and NN skin in psoriasis 
name PP NN log2(PP/NN) p-value 
chr1:114585534-114585536_-|chr1:114581390-114581392_- 1.90 0.57 1.74 0.00 
chr1:156705436-156705439_-|chr19:30548305-30548308_+ 5.95 0.76 2.97 0.00 
chr1:187284711-187284713_+|chr3:100555262-100555264_+ 2.43 0.76 1.67 0.00 
chr1:221146521-221146523_+|chr12:52680386-52680388_- 4.19 0.90 2.21 0.00 
chr1:46683297-46683301_-|chr1:46665362-46665366_- 1.62 0.57 1.50 0.00 
chr10:117290183-117290187_-|chr10:117270441-117270445_- 2.05 0.76 1.43 0.00 
chr10:130588015-130588018_-|chr1:153615019-153615022_- 3.00 0.67 2.17 0.00 
chr11:119018284-119018299_-|chr5:116052284-116052299_- 7.14 2.71 1.40 0.01 
chr11:18588993-18588995_+|chr11:18601089-18601091_+ 2.33 0.86 1.44 0.00 
chr11:6603403-6603405_-|chr11:6592823-6592825_- 2.57 1.10 1.23 0.00 
chr12:12338419-12338421_-|chr12:12322554-12322556_- 2.86 0.57 2.32 0.00 
chr12:52208873-52208875_+|chr12:52223443-52223445_+ 3.05 0.76 2.00 0.00 
chr13:31946179-31946181_+|chr13:32038427-32038429_+ 3.05 1.14 1.42 0.00 
chr15:79560455_-|chr13:113585965_+ 3.67 1.43 1.36 0.00 
chr16:82170598_-|chr16:82164194_- 5.76 1.38 2.06 0.00 
chr17:75131183-75131184_+|chr17:75148435-75148436_+ 1.57 0.57 1.46 0.00 
chr17:82496865-82496871_+|chr17:82563350-82563356_+ 1.81 0.90 1.00 0.00 
chr18:63842217-63842218_+|chr18:63891434-63891435_+ 21.81 6.71 1.70 0.00 
chr2:83058905-83058909_-|chr10:5499269-5499273_- 8.48 3.86 1.14 0.00 
chr20:3822289-3822293_+|chr20:3854553-3854557_+ 2.81 0.95 1.56 0.00 
chr22:41680243-41680244_-|chr22:41667009-41667010_- 2.19 0.67 1.72 0.00 
chr22:50544785-50544788_-|chr22:50542898-50542901_- 12.29 0.57 4.43 0.00 
chr5:141651534-141651540_-|chr5:141651115-141651121_- 15.48 0.38 5.34 0.00 
chr5:160929220-160929223_-|chr5:160785802-160785805_- 6.57 2.00 1.72 0.00 
chr5:75047896-75047898_-|chr5:75030038-75030040_- 28.71 5.24 2.45 0.00 
chr5:75053513-75053514_-|chr5:75048036-75048037_- 11.48 2.33 2.30 0.00 
chr5:75053514_-|chr5:75030038_- 4.67 0.57 3.03 0.00 
chr5:75053947-75053948_-|chr5:75048036-75048037_- 6.29 2.24 1.49 0.00 
chr5:95838441-95838444_+|chr5:95856875-95856878_+ 11.05 2.86 1.95 0.00 
chr6:28080968-28080970_+|chr6:28085478-28085480_+ 5.67 2.10 1.44 0.00 
chr6:53929576-53929579_+|chr6:53982755-53982758_+ 2.48 0.76 1.70 0.00 
chr6:7052092-7052097_+|chr6:7176652-7176657_+ 1.67 0.62 1.43 0.00 
chr9:135938219-135938224_-|chr9:135925185-135925190_- 2.76 0.62 2.16 0.00 
chrX:153446008-153446010_-|chrX:153441548-153441550_- 2.62 0.67 1.97 0.00 




Chimeric RNAs significantly down-regulated between PP and NN skin in psoriasis 
name PP NN log2(PP/NN) p-value 
chr1:109445925-109445929_+|chr14:20343349-20343353_- 0.00 14.86 -7.22 0.00 
chr1:152314598-152314600_-|chrX:121147118-121147120_- 0.00 9.29 -6.54 0.00 
chr1:152355667-152355670_-|chr9:74121604-74121607_- 2.48 9.48 -1.94 0.00 
chr1:153262111-153262114_+|chr13:56182412-56182415_+ 0.00 4.95 -5.63 0.00 
chr1:160406170-160406175_-|chr1:160340293-160340298_- 1.95 12.62 -2.69 0.01 
chr1:224175417-224175420_-|chr8:101178386-101178389_- 0.67 1.76 -1.40 0.00 
chr1:9871186-9871187_-|chr1:9773394-9773395_- 0.38 1.95 -2.36 0.00 
chr11:62518405-62518407_-|chr1:22373684-22373686_+ 0.57 1.76 -1.62 0.01 
chr11:62665550-62665554_+|chrX:9808117-9808121_- 0.00 6.95 -6.12 0.00 
chr12:109879105-109879108_+|chr12:109903023-109903026_+ 1.00 3.00 -1.58 0.01 
chr12:24562822-24562825_-|chr12:24407565-24407568_- 0.43 2.33 -2.44 0.00 
chr13:104718251-104718253_-|chr12:6510358-6510360_+ 0.00 23.24 -7.86 0.00 
chr13:51827459-51827462_-|chr1:153614593-153614596_- 0.00 4.38 -5.45 0.00 
chr13:97976327-97976333_+|chr19:35497440-35497446_- 0.00 2.29 -4.51 0.00 
chr14:20343245-20343247_-|chr12:83269668-83269670_+ 0.00 4.76 -5.57 0.00 
chr15:52934997-52934999_+|chr1:152350840-152350842_- 0.00 6.00 -5.91 0.00 
chr17:18040714-18040718_-|chr17:18039048-18039052_- 1.33 3.00 -1.17 0.00 
chr17:40822043-40822045_-|chr3:23480087-23480089_- 0.00 4.48 -5.48 0.00 
chr17:40822471-40822476_-|chr10:31636001-31636006_+ 0.00 6.43 -6.01 0.00 
chr17:40822478-40822480_-|chr12:117849353-117849355_+ 0.00 3.95 -5.30 0.00 
chr18:31355790-31355793_+|chr5:82146722-82146725_- 0.00 7.29 -6.19 0.00 
chr19:48298676-48298680_+|chr18:31127978-31127982_- 0.00 3.86 -5.27 0.00 
chr2:224535863-224535865_+|chr1:152357404-152357406_- 0.00 3.52 -5.14 0.00 
chr2:27672859-27672861_+|chr12:52674976-52674978_- 0.00 6.86 -6.10 0.00 
chr2:64488838-64488844_+|chr2:64551438-64551444_+ 0.24 5.00 -4.39 0.00 
chr2:64500920-64500925_+|chr2:64551440-64551445_+ 0.48 5.67 -3.57 0.00 
chr20:13221143-13221144_+|chr20:13270502-13270503_+ 0.33 1.81 -2.44 0.00 
chr21:45021667-45021669_+|chr12:52677457-52677459_- 0.00 6.57 -6.04 0.00 
chr22:20464262-20464267_-|chr20:17962828-17962833_- 0.00 15.19 -7.25 0.00 
chr3:156490801-156490804_-|chr11:65501034-65501037_+ 0.00 5.43 -5.76 0.00 
chr4:168324837-168324841_-|chr4:168311364-168311368_- 2.67 22.48 -3.08 0.00 
chr5:149867232-149867234_+|chr9:35657877-35657879_- 0.00 193.95 -10.92 0.00 
chr5:45824570-45824573_+|chr14:20343254-20343257_- 0.00 2.90 -4.86 0.00 
chr5:95055283-95055285_+|chr17:40818455-40818457_- 0.00 9.52 -6.57 0.00 
chr7:94369097-94369100_+|chr9:35657988-35657991_- 0.00 39.19 -8.61 0.00 
chr7:94369098-94369100_+|chr9:35657988-35657990_- 0.00 4.76 -5.57 0.00 
chr8:15900413-15900418_+|chr17:40819701-40819706_- 0.00 20.90 -7.71 0.00 
chr9:35657762-35657764_-|chr7:50628592-50628594_+ 0.00 13.76 -7.10 0.00 
chrX:120315742-120315745_-|chrX:120304490-120304493_- 0.33 2.52 -2.92 0.00 
* PP: average expression level in PP. NN: average expression level in NN. log2(PP/NN): log2 fold change of PP vs. NN. 
 
